Biomarker Core

项目摘要--生物标志物核心(核心G) 威斯康星州阿尔茨海默病研究中心的生物标记物核心(BMC)代表 在活体内观察大脑以获得阿尔茨海默氏症生物标志的能力和基础设施 疾病(AD)和相关障碍以及表征大脑健康和 恢复力。由于AD的临床前时间框架是ADRC的一个主要重点，而且由于它越来越多地 了解到AD的病理早在其症状出现之前就发生了，这个收费的核心就是提供 为调查人员提供必要的能力、工具和基础设施，以尽可能准确地确定 阿尔茨海默病的早期体内变化、风险和复原力因素的影响以及预防策略对相关因素的影响 生物标志物。核心将集中在收集、质量检查和管理几种与AD相关的类型 生物标志物包括a)由淀粉样斑块和神经原纤维缠结定义的AD标志物，以及 可通过分子PET成像或脑脊液(CSF)分析确定；b)脑血管标志物 疾病--认知功能减退的第二大常见病因，可通过新的核磁共振确定 方法；c)通过脑脊液或PET获得的其他神经退行性疾病的标志物；和d) 一般大脑健康的标志包括突触密度、神经元损伤、萎缩、连接、炎症、 和血流，这是可能的通过PET，MRI和脑脊液模式。为了实现这些目标，我们将 实现以下目标：目标1：获得阿尔茨海默病标志性神经病理特征的生物标志物-- 脑脊液和/或分子PET成像显示淀粉样斑块和神经原纤维缠绕。目标2：收集生物标志物 伴随的特征，如血管疾病、炎症和神经元死亡。目标3：制定方法 用于解释生物标志物读数，特别是淀粉样蛋白(A)、tau(T)和神经变性(N)的读数。目标4： 为ADRC调查人员提供基础设施和分析支持。目标5：共享图像、流体和派生图像 与国家阿尔茨海默氏症协调中心(NACC)、当地调查人员和其他合格人员的数据 世界各地的调查人员。目标6：扩大中心的生物标记物能力，包括a)采用新的 这一快速变化领域的方法和模式，以及b)协调以前收集的数据或多站点 具有当前或未来收集方法的数据。BMC将与ADRC的其他核心互动工作，以 尽可能高效地满足ADRC调查人员的需求，并向NACC和 因此，我们作为一个领域，可以在检测和有效干预AD方面更快地得出答案。

PROJECT SUMMARY- BIOMARKER CORE (CORE G) The Biomarker Core (BMC) of the Wisconsin Alzheimer's Disease Research Center (ADRC) represents the capability and infrastructure for peering into the brain in vivo to obtain biological markers of Alzheimer's disease (AD) and related disorders and non-disease-specific qualities characterizing brain health and resilience. Since the pre-clinical time frame of AD is a major emphasis of the ADRC, and since it is increasingly understood that AD pathology occurs well before its symptoms, the charge of this core is to provide the necessary capabilities, tools, and infrastructure to investigators to characterize as accurately as possible the early in-vivo changes of AD, effect of risk and resilience factors, and effect of prevention strategies on relevant biomarkers. The core will focus on collecting, quality checking, and curating several types of AD-relevant biomarkers including a) markers indicative of AD - defined by amyloid plaques and neurofibrillary tangles, and ascertainable by molecular PET imaging or cerebrospinal fluid (CSF) assays; b) markers of cerebrovascular diseases - the second most common etiology (or etiologies) of cognitive decline and ascertainable by new MRI methods; c) markers of other neurodegenerative diseases as they become available via CSF or PET; and d) markers of general brain health including synaptic density, neuronal injury, atrophy, connectivity, inflammation, and blood flow that are possible through PET, MRI and CSF modalities. To meet these goals, we will accomplish the following aims: Aim 1: Obtain biological markers of AD's hallmark neuropathological features - amyloid plaques and neurofibrillary tangles with CSF and/or molecular PET imaging. Aim 2: Collect biomarkers of concomitant features, such as vascular disease, inflammation, and neuronal death. Aim 3: Develop method for interpreting biomarker readouts, particularly for Amyloid (A), tau (T) and neurodegeneration (N). Aim 4: Support ADRC investigators with infrastructure and analytic support. Aim 5: Share images, fluid, and derived data with the National Alzheimer's Coordinating Center (NACC), local investigators, and other qualified investigators throughout the world. Aim 6: Expand the Center's biomarker capability, including a) adopting new methods and modalities in this fast-changing field, and b) for harmonizing previously collected data or multi-site data with current or future collection methods. The BMC will work interactively with the other ADRC cores to serve the needs of the ADRC investigators as efficiently as possible and deliver high quality data to NACC and other users so we, as a field, can come to answers faster in detecting and intervening effectively in AD.